Literature DB >> 32424636

Clinical outcomes and survivals after total en bloc spondylectomy for metastatic leiomyosarcoma in the spine.

Satoshi Kato1, Satoru Demura2, Kazuya Shinmura2, Noriaki Yokogawa2, Noritaka Yonezawa2, Takaki Shimizu2, Norihiro Oku2, Ryo Kitagawa2, Hideki Murakami3, Norio Kawahara4, Katsuro Tomita2, Hiroyuki Tsuchiya2.   

Abstract

PURPOSE: Leiomyosarcoma (LMS) is generally resistant to radiation and chemotherapy. Our study aimed to examine the outcomes of total en bloc spondylectomy (TES) for spinal metastatic LMS and to analyze potential factors associated with survival.
METHODS: This study included 10 consecutive patients who underwent TES for spinal metastatic LMS at our institute between 2005 and 2016 and were followed up at a minimum of 3 years after surgery. At the time of TES, all the 10 patients had solitary bone metastases in the spine. Seven patients had a lowered performance status (PS) with an eastern cooperative oncology group (ECOG) grade of 2 or 3 due to back pain or neurological symptoms. The cancer-specific survival (CSS) time from TES to death or last follow-up was the main endpoint. Potential factors associated with survival were evaluated using the Kaplan-Meier analysis and the log-rank test.
RESULTS: Five patients underwent a single vertebral resection, and the other five patients underwent two or three consecutive vertebral resections. Three patients developed perioperative complications including pulmonary thromboembolism and pneumothorax. Nine patients improved or fairly maintained their PS with an ECOG grade of 1. The 1-, 3-, and 5-year CSS rates after TES were 90%, 70%, and 47%, respectively. Only postoperative disability (ECOG PS grade 3) was significantly associated with short-term survival after TES.
CONCLUSIONS: The clinical outcomes of 10 patients who underwent TES for spinal metastatic LMS were favorable without severe complications. Postoperative disability was significantly associated with short-term survival after TES.

Entities:  

Keywords:  Clinical outcome; Leiomyosarcoma; Spinal metastasis; Survival; Total en bloc spondylectomy

Mesh:

Year:  2020        PMID: 32424636     DOI: 10.1007/s00586-020-06461-0

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  5 in total

1.  Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy.

Authors:  Satoshi Kato; Satoru Demura; Hideki Murakami; Kazuya Shinmura; Noriaki Yokogawa; Ryohei Annen; Motoya Kobayashi; Yohei Yamada; Satoshi Nagatani; Norio Kawahara; Hiroyuki Tsuchiya
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

2.  Bone Metastases in Patients with Leiomyosarcoma: A Retrospective Analysis of Survival and Surgical Management.

Authors:  Christa L LiBrizzi; Ashish Vankara; Christian F Meyer; Adam S Levin; Carol D Morris
Journal:  Sarcoma       Date:  2022-05-06

Review 3.  Metastasectomy in Leiomyosarcoma: A Systematic Review and Pooled Survival Analysis.

Authors:  Megan Delisle; Bader Alshamsan; Kalki Nagaratnam; Denise Smith; Ying Wang; Amirrtha Srikanthan
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 4.  Holistic Approach to the Diagnosis and Treatment of Patients with Tumor Metastases to the Spine.

Authors:  Hanna Nowak; Dominika Maria Szwacka; Monika Pater; Wojciech Krzysztof Mrugalski; Michał Grzegorz Milczarek; Magdalena Staniszewska; Roman Jankowski; Anna-Maria Barciszewska
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

Review 5.  Surgical Metastasectomy in the Spine: A Review Article.

Authors:  Satoshi Kato; Satoru Demura; Kazuya Shinmura; Noriaki Yokogawa; Takaki Shimizu; Hideki Murakami; Norio Kawahara; Katsuro Tomita; Hiroyuki Tsuchiya
Journal:  Oncologist       Date:  2021-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.